Upstream Bio (UPB) announced two upcoming poster presentations at the American Thoracic Society 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps. The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
- 3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
- Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
- VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
- Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
- Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls